NEW YORK, Jan. 06, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of TerraVia Holdings, Inc. securities (NASDAQ:TVIA) from August 8, 2016 through November 7, 2016, inclusive (the “Class Period”).
Investors who have incurred losses in TerraVia Holdings, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may also review the filed complaint and obtain additional information concerning the action on our website, www.whafh.com.
If you purchased the securities of TerraVia Holdings, Inc. within the class period and suffered losses, you may, no later than January 17, 2017, request that the Court appoint you lead plaintiff of the proposed class.
According to the filed complaint, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) TerraVia’s products caused gastrointestinal distress, such as nausea and vomiting; and (2) as a result, Defendants’ statements about TerraVia’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.
On November 7, 2016, Bloomberg reported that TerraVia sent a letter to a distributor in July warning that TerraVia had received reports showing that algal protein can cause gastrointestinal distress. On this news, shares of TerraVia fell 8.1% to close at $1.70 per share on November 7, 2016, damaging investors.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774


Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 



